Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs

Contact: Kurt Leutzinger Abgenix, Inc. Vice President and Chief Financial Officer (510) 608-6575 Marion E. Glick Porter Novelli (212) 601-8273 Mark R. Vincent CuraGen Corporation Director, Corporate Communications 1-888-GENOMICS www.curagen.com ABGENIX AND CURAGEN ESTABLISH LARGE-SCALE DRUG DEVELOPMENT ALLIANCE Companies to Develop Genomics-based Human Antibody Drugs Fremont, CA and New Haven, CT - December 9, 1999 - Abgenix, Inc. (Nasdaq: ABGX), an antibody-based biopharmaceutical company and CuraGen Corporation (Nasdaq: CRGN), an integrated genomics-based drug discovery and development company, announced today the formation of a strategic alliance to develop and commercialize genomics-based antibody drugs using XenoMouse technology. This five-year alliance has been established to identify up to 120 fully human antibody drugs intended for treating a broad range of complex diseases including cancer and autoimmune disorders. Antibodies to cancer antigens in CuraGen's database will be generated exclusively with Abgenix' XenoMouse technology during this alliance. Under the terms of this agreement, Abgenix will purchase $15 million of CuraGen common stock and CuraGen will provide research support payments of $1.5 million per year. In addition, both companies will receive reciprocating milestone and royalty payments for products resulting from this drug development alliance. "Abgenix is impressed with CuraGen's technical capabilities with integrated genomics-based drug discovery and development," stated R. Scott Greer, president and CEO of Abgenix. "This strategic alliance complements our existing relationship with Human Genome Sciences and significantly expands our presence in the genomics field. We are also pleased to be joining Biogen and Genentech as corporate partners with equity stakes in CuraGen." "This strategic alliance changes the drug development landscape by establishing a powerful platform for producing genomics-base

Contact: Kurt Leutzinger, Abgenix, Inc.
Porter Novelli

Page: 1 2 3 4

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix initiates phase III clinical trial of graft versus host disease therapy
3. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. Tufts University establishes $4 million dollar tissue engineering resource center
8. Corals can reestablish symbiosis with algae from their environments after bleaching
9. Researchers establish first molecular link between eating and aging
10. DFG establishes first German-Sino Research Training Group
11. New Woods Hole Center for Oceans and Human Health established

Post Your Comments:

(Date:8/7/2020)... ... August 06, 2020 , ... ... in the prestigious National STEM Scholar Program, a unique professional development program that ... project support for middle school science teachers nationwide. , Created in partnership between ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... therapeutics product portfolio with a near term focus on Type 2 diabetes and ... commercialization experience across multiple therapeutic areas and classes. As Chief Commercial Officer, Justin ...
(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
Breaking Biology News(10 mins):
(Date:7/22/2020)... , ... July 22, 2020 , ... Join experts from ... Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar on ... regulating body in China for drugs and medical devices. Specifically, for medical devices, the ...
(Date:7/10/2020)... ... July 08, 2020 , ... Bode Technology, a ... laboratory operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume ... Bode-CARES provides a turnkey solution that includes a comprehensive collection and virus-management ...
(Date:7/7/2020)... ... July 06, 2020 , ... ... from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, ... has hosted an elite awards program, highlighting outstanding examples of how technology innovations ...
(Date:6/28/2020)... SAN JOSE, Calif. (PRWEB) , ... June 25, ... ... the globe, researchers are racing to develop a vaccine or drug treatment. In ... company Recursion has publicly released the world’s largest imaging dataset portraying ...
Breaking Biology Technology:
Cached News: